| Literature DB >> 28767690 |
Kang-Cheng Su1,2,3, Yu Ru Kou2, Fang-Chi Lin1, Chieh-Hung Wu1, Jia-Yih Feng1, Shiang-Fen Huang4, Tao-Fen Shiung5, Kwei-Chun Chung5, Yu-Hsiu Tung5, Kuang-Yao Yang1,6,7, Shi-Chuan Chang1,3,7.
Abstract
BACKGROUND: To investigate the effect of a simplified prevention bundle with alcohol-based, dual hand hygiene (HH) audit on the incidence of early-onset ventilation-associated pneumonia (VAP).Entities:
Mesh:
Year: 2017 PMID: 28767690 PMCID: PMC5540591 DOI: 10.1371/journal.pone.0182252
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study algorithm.
Shadowed areas indicate periods of bundle implementation for each specific preventive measure. HCWs, healthcare workers; eHH, unaware external hand hygiene audited by non-unit-based observers; iHH, aware internal hand hygiene audited by unit-based observers.
Fig 2Incidence of total ventilator-associated pneumonia (VAP) during different study periods.
Total VAP incidence (events/1000 ventilator days) and compliance of oral care (OC), aware internal hand hygiene audit (iHH) as well as unaware external hand hygiene audit (eHH) were illustrated at monthly intervals (A) and at quarterly intervals (B). PDCA means plan-do-check-act cycle in case of decrease in compliance monitoring.
Demographic characteristics in different study phases.
| Characteristics | Phase 1 (n = 158) | Phase 2 (n = 37) | Phase 3 (n = 191) | Phase 4 (n = 67) | |
|---|---|---|---|---|---|
| 64.8 ± 14.3 | 66.7 ± 14.9 | 66.3 ± 16.1 | 67.6 ± 16.6 | 0.606 | |
| 114 (72.2) | 21 (56.8) | 125 (65.4) | 46 (68.7) | 0.271 | |
| 26.2 ± 6.1 | 26.5 ± 5.6 | 26.9 ± 5.2 | 27.4 ± 6.3 | 0.426 | |
| 119 (75.3) | 29 (78.4) | 153(80.1) | 52 (77.6) | 0.864 | |
| 80 (50.6) | 18 (48.6) | 91 (47.6) | 33 (49.3) | 0.979 | |
| 59 (37.3) | 16 (43.2) | 69 (36.1) | 28 (41.8) | 0.487 | |
| 45 (28.5) | 11 (29.7) | 51 (26.7) | 20 (29.9) | 0.961 | |
| 30 (19.0) | 6 (16.2) | 30 (15.7) | 9 (13.4) | 0.721 | |
| | 12 (7.6) | 3 (8.1) | 14 (7.3) | 5 (7.5) | 0.992 |
| 74 (46.8) | 24 (64.9) | 117 (61.3) | 39 (59.1) | 0.060 | |
| 57 (36.1) | 7 (18.9) | 48 (25.1) | 19 (28.8) | 0.053 | |
| 11 (6.9) | 3 (8.1) | 11 (5.8) | 4 (6.0) | 0.933 | |
| 16 (10.1) | 3 (8.1) | 15 (7.9) | 5 (7.5) | 0.941 | |
| | 42 (26.6) | 8 (22.9) | 53 (27.7) | 17 (25.3) | 0.856 |
| 44 (27.8) | 6 (17.1) | 52 (27.2) | 11 (16.4) | 0.068 | |
| 34 (22.8) | 8 (21.6) | 34 (17.8) | 14 (20.9) | 0.839 | |
| 14 (8.9) | 3 (8.1) | 22 (11.5) | 6 (8.9) | 0.804 | |
| 8 (5.1) | 2 (5.4) | 8 (4.2) | 3 (4.5) | 0.984 | |
| | 12 (7.6) | 5 (13.5) | 16 (8.4) | 6 (9.0) | 0.439 |
Continuous variables are presented as mean ± SD. Categorical variables are presented as counts and percentages in parentheses.
APACHE, acute physiology and chronic health evaluation; ICU, intensive care unit; CABG, coronary artery bypass graft; TAA, thoracic aortic aneurysm; AAA, abdominal aortic aneurysm.
aANOVA test.
bChi-square test.
cChronic lung disease includes chronic pulmonary obstructive disease, asthma, bronchiectasis, and interstitial lung disease.
dValve repair indicates valvular surgery for mitral and aortic valve.
eSupporting device includes extracorporeal membrane oxygenation and ventricular assisted device.
Fig 3The total, clinical and microbiological VAP incidences during different study periods.
Poisson regression, * P < 0.05, vs. phases 1 and 2, respectively; # P < 0.05, vs. phase 1.
ICU outcomes in different study phases.
| Phase 1 (n = 158) | Phase 2 (n = 37) | Phase 3 (n = 191) | Phase 4 (n = 67) | ||
|---|---|---|---|---|---|
| 5.5 ± 1.7 | 6.0 ± 1.3 | 5.6 ± 1.7 | 5.9 ± 1.6 | 0.248 | |
| 12 (7.6) | 0 | 8 (5.3) | 4 (6.0) | 0.351 | |
| 73 (33.3) | 14 (37.8) | 88 (46.1) | 23 (34.3) | 0.055 | |
| 12.2 ± 15.9 | 14.1 ± 15.1 | 12.4 ± 17.4 | 14.8 ± 19.9 | 0.702 | |
| 36 (22.8) | 4 (10.8) | 40 (20.9) | 11 (16.4) | 0.341 | |
| 120 (75.9) | 29 (78.4) | 146 (76.4) | 54 (80.6) | 0.882 | |
| 13.7 ± 15.5 | 18.9 ± 15.8 | 14.6 ± 17.9 | 17.5 ± 20.4 | 0.228 | |
| 10.0 ± 4.7 | 11.9 ± 3.5 | 10.6 ± 4.4 | 11.0 ± 4.3 | 0.092 | |
| 37.4 ± 28.9 | 47.4 ± 30.4 | 41.8 ± 37.1 | 41.5 ± 30.7 | 0.331 | |
| - | 22.0 | 88.8 | - | < 0.001 | |
| 72.9 | 73.2 | 82.5 | 84.5 | 0.084 | |
| - | 78.5 | 90.6 | 94.9 | 0.002 |
Continuous variables are presented as mean ± SD. Categorical variables are presented as counts and percentages in parentheses.
ICU, intensive care unit; MV, mechanical ventilation.
aANOVA test.
bChi-square test.
cTotal antibiotic days mean the total days of the patients receiving antibiotic treatment in the first 14 days after commencement of mechanical ventilation.
Fig 4Correlation between total VAP incidence and compliance for A, oral care; B, unaware external hand hygiene audit (eHH); and C, aware internal hand hygiene audit (iHH) (Spearman’s correlation).
Total ventilator-associated pneumonia incidence stratified by variable cut-off value for different bundle component.
| Compliance with variable | Total VAP incidence | Rate ratio (95% CI) (High | ||
|---|---|---|---|---|
| ≥ CO | < CO | |||
| 15.6 | 31.6 | 0.50 (0.21–1.16) | 0.124 | |
| 15.6 | 31.6 | 0.50 (0.21–1.16) | 0.124 | |
| 8.9 | 31.8 | 0.28 (0.11–0.71) | 0.004 | |
| 6.6 | 31.4 | 0.21 (0.07–0.62) | 0.001 | |
| 5.3 | 25.2 | 0.21 (0.05–0.89) | 0.009 | |
| 18.3 | 43.1 | 0.42 (0.26–0.68) | < 0.001 | |
| 13.8 | 35.1 | 0.39 (0.22–0.71) | 0.001 | |
| 11.8 | 31.1 | 0.38 (0.17–0.83) | 0.006 | |
| 0 | 26.6 | - | - | |
| 18.1 | 56.6 | 0.32 (0.10–1.05) | 0.105 | |
| 18.1 | 56.6 | 0.32 (0.10–1.06) | 0.105 | |
| 18.6 | 24.3 | 0.76 (0.29–2.01) | 0.597 | |
| 19.3 | 19.5 | 0.99 (0.47–2.04) | 0.976 | |
| 17.3 | 19.8 | 0.88 (0.34–2.27) | 0.781 | |
CO, cut off value; CI, confidence interval.
aVAP incidence indicates VAP events per 1000 ventilator days.
bPoisson regression.